JP2016034978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016034978A5 JP2016034978A5 JP2015236260A JP2015236260A JP2016034978A5 JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5 JP 2015236260 A JP2015236260 A JP 2015236260A JP 2015236260 A JP2015236260 A JP 2015236260A JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eculizumab
- pnh
- treatment
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 229960002224 eculizumab Drugs 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78307006P | 2006-03-15 | 2006-03-15 | |
| US60/783,070 | 2006-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Division JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Division JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016034978A JP2016034978A (ja) | 2016-03-17 |
| JP2016034978A5 true JP2016034978A5 (enExample) | 2016-09-23 |
| JP6224059B2 JP6224059B2 (ja) | 2017-11-01 |
Family
ID=38222520
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US20090220508A1 (enExample) |
| EP (5) | EP4316465A3 (enExample) |
| JP (9) | JP2009530299A (enExample) |
| KR (2) | KR20080110800A (enExample) |
| AU (1) | AU2007225044C1 (enExample) |
| BR (2) | BRPI0708909B8 (enExample) |
| CA (2) | CA3022097C (enExample) |
| DK (1) | DK2359834T5 (enExample) |
| ES (2) | ES2965283T3 (enExample) |
| HU (2) | HUE066795T2 (enExample) |
| IL (4) | IL302157A (enExample) |
| MX (2) | MX340784B (enExample) |
| PL (2) | PL2359834T3 (enExample) |
| PT (1) | PT2359834T (enExample) |
| SI (1) | SI2359834T1 (enExample) |
| WO (1) | WO2007106585A1 (enExample) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| WO2007106585A1 (en) | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| HRP20150279T1 (hr) * | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BRPI0916668B1 (pt) | 2008-08-05 | 2021-12-28 | Novartis Ag | Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor |
| CN109045296A (zh) * | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| NZ599813A (en) * | 2009-11-09 | 2014-07-25 | Alexion Pharma Inc | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| CA2827170A1 (en) | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| AP2014007761A0 (en) | 2011-12-21 | 2014-07-31 | Novartis Ag | Compositions and methods for antibodies targeting factor P |
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| HK1204693A1 (en) * | 2012-03-16 | 2015-11-27 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| WO2014160958A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| HRP20210013T1 (hr) * | 2013-08-28 | 2021-04-02 | Ipc Research, Llc | Stabilni polipeptidi koji se vezuju za ljudski komplement c5 |
| TR201911279T4 (tr) | 2013-08-28 | 2019-08-21 | Affibody Ab | Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması. |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| PL3154561T3 (pl) | 2014-06-12 | 2019-12-31 | Ra Pharmaceuticals, Inc. | Modulowanie aktywności dopełniacza |
| MX2017001531A (es) | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| CN113121415B (zh) | 2014-09-29 | 2025-09-02 | 凯莫森特里克斯股份有限公司 | 制备C5aR拮抗剂的方法和中间体 |
| WO2016061066A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of replicating a large scale eculizumab production cell culture |
| EP3207058A1 (en) * | 2014-10-15 | 2017-08-23 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| US9908932B2 (en) | 2014-10-15 | 2018-03-06 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| PT3221359T (pt) | 2014-11-17 | 2020-06-23 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| JP2018511557A (ja) | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | ２種以上の抗ｃ５抗体の組み合わせおよび使用方法 |
| HRP20211824T1 (hr) | 2015-01-28 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulatori aktivnosti komplementa |
| JP7133925B2 (ja) | 2015-03-23 | 2022-09-09 | アレクシオン ファーマシューティカルズ インコーポレイテッド | ウイルス濾過 |
| JP6773679B2 (ja) | 2015-03-30 | 2020-10-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域 |
| US20190135903A1 (en) * | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
| MX387517B (es) | 2015-04-06 | 2025-03-18 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
| JP6999421B2 (ja) | 2015-04-07 | 2022-02-04 | アレクトル エルエルシー | 抗ソルチリン抗体及びその使用方法 |
| EP3307318A4 (en) | 2015-06-09 | 2019-01-16 | Children's Hospital Medical Center | DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017040301A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| EP3328885A1 (en) | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| JP7725185B2 (ja) | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US11203634B2 (en) | 2015-10-07 | 2021-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody |
| KR20180084817A (ko) | 2015-10-29 | 2018-07-25 | 알렉터 엘엘씨 | 항-siglec-9 항체 및 이의 이용 방법 |
| RS60134B1 (sr) | 2015-12-16 | 2020-05-29 | Ra Pharmaceuticals Inc | Modulatori aktivnosti komplementa |
| CN108601790A (zh) | 2016-01-14 | 2018-09-28 | 凯莫森特里克斯股份有限公司 | C3肾小球病的治疗方法 |
| US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
| PL3426680T3 (pl) | 2016-03-10 | 2025-03-31 | Acceleron Pharma Inc. | Białka wiążące receptor aktywiny typu 2 i ich zastosowania |
| JP7103950B2 (ja) | 2016-04-22 | 2022-07-20 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合性タンパク質及びその使用 |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| LT3468990T (lt) | 2016-06-14 | 2024-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antikūnai ir jų panaudojimas |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| ES2848206T3 (es) | 2016-10-19 | 2021-08-05 | Alexion Pharma Inc | Un método de cuantificar C5 sin unir en una muestra |
| BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
| CN110087683A (zh) * | 2016-12-16 | 2019-08-02 | 三星Bioepis股份有限公司 | 稳定水性抗c5抗体组合物 |
| WO2018143266A1 (en) | 2017-01-31 | 2018-08-09 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| WO2018217638A1 (en) | 2017-05-22 | 2018-11-29 | Alexion Pharmaceuticals Inc. | Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients |
| AU2018281337B2 (en) | 2017-06-06 | 2022-08-25 | Relinia, Inc. | Single-chain TNF receptor 2 agonist fusion proteins |
| CN116271012A (zh) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | 高浓度抗c5抗体制剂 |
| CN111163767A (zh) | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
| CN110662765B (zh) | 2017-08-03 | 2023-09-29 | 艾利妥 | 抗cd33抗体及其使用方法 |
| RS64419B1 (sr) | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 antitela i postupci za njihovu upotrebu |
| BR112020008182A2 (pt) | 2017-10-26 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua) |
| EA202091198A1 (ru) | 2017-11-14 | 2020-09-09 | Эрселлкс, Инк. | Полипептиды, содержащие домен d, и их применение |
| US12037389B2 (en) | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| KR20200095485A (ko) * | 2017-12-04 | 2020-08-10 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| CN111886246B (zh) | 2017-12-29 | 2024-12-17 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| JP7382970B2 (ja) | 2018-06-08 | 2023-11-17 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 |
| MX2020013798A (es) * | 2018-06-19 | 2021-08-11 | Atarga Llc | Moléculas de anticuerpo de componente de complemento 5 y sus usos. |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| CA3099176A1 (en) | 2018-06-29 | 2020-01-02 | Alector Llc | Anti-sirp-beta1 antibodies and methods of use thereof |
| PE20210186A1 (es) | 2018-07-13 | 2021-02-02 | Alector Llc | Anticuerpos anti-sortilina y metodos para su uso |
| EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| CA3107618A1 (en) | 2018-08-01 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| AU2019331018A1 (en) | 2018-08-31 | 2021-03-11 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| US11807627B2 (en) | 2018-09-25 | 2023-11-07 | Achillon Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| WO2020092549A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| CA3123583A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| AU2020245434A1 (en) | 2019-03-22 | 2021-09-30 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| CA3140023A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Anti-sortilin antibodies for use in therapy |
| KR20240033090A (ko) | 2019-07-31 | 2024-03-12 | 에프. 호프만-라 로슈 아게 | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
| AU2020319677A1 (en) | 2019-07-31 | 2022-01-06 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab |
| KR20220058540A (ko) | 2019-07-31 | 2022-05-09 | 알렉터 엘엘씨 | 항-ms4a4a 항체 및 이의 사용 방법 |
| US20220259305A1 (en) | 2019-08-05 | 2022-08-18 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| WO2021113655A1 (en) | 2019-12-05 | 2021-06-10 | Alector Llc | Methods of use of anti-trem2 antibodies |
| AU2020403021A1 (en) | 2019-12-12 | 2022-06-23 | Alector Llc | Methods of use of anti-CD33 antibodies |
| CA3160210A1 (en) | 2019-12-13 | 2021-06-17 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| CA3167851A1 (en) | 2020-02-24 | 2021-09-02 | Francesca CIGNARELLA | Methods of use of anti-trem2 antibodies |
| EP4126937A1 (en) | 2020-03-31 | 2023-02-08 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
| EP4126953A2 (en) | 2020-04-03 | 2023-02-08 | Alector LLC | Methods of use of anti-trem2 antibodies |
| CN116406287A (zh) | 2020-04-16 | 2023-07-07 | 巴黎公共医疗救助机构 | 治疗由病毒引起的补体介导的障碍的方法 |
| WO2021231470A1 (en) | 2020-05-12 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| KR20230117169A (ko) | 2020-12-02 | 2023-08-07 | 알렉터 엘엘씨 | 항-소르틸린 항체의 사용 방법 |
| US20240174746A1 (en) | 2021-03-18 | 2024-05-30 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
| US20240166738A1 (en) | 2021-03-23 | 2024-05-23 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
| EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| JP2024527262A (ja) | 2021-06-16 | 2024-07-24 | アレクトル エルエルシー | 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法 |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| EP4482523A1 (en) | 2022-02-23 | 2025-01-01 | Alector LLC | Methods of use of anti-trem2 antibodies |
| KR20250036813A (ko) | 2022-07-12 | 2025-03-14 | 싸이톰스 테라퓨틱스, 인크. | Epcam 면역접합체 및 이의 용도 |
| CN119866348A (zh) | 2022-07-29 | 2025-04-22 | 艾莱克特有限责任公司 | 抗gpnmb抗体及其使用方法 |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| EP4646270A2 (en) | 2023-01-06 | 2025-11-12 | Alector LLC | Anti-il18 binding protein antibodies and methods of use thereof |
| WO2025072726A1 (en) | 2023-09-29 | 2025-04-03 | Trex Bio, Inc. | Tnf-alpha variant fusion molecules |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| WO1992010205A1 (en) | 1990-12-06 | 1992-06-25 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US6027725A (en) | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| WO1996009043A1 (en) | 1994-09-23 | 1996-03-28 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| AU2001234962A1 (en) | 2000-02-10 | 2001-08-20 | Alexion Pharmaceuticals, Inc. | Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| WO2002030985A2 (en) | 2000-10-10 | 2002-04-18 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| ES2258558T3 (es) * | 2000-12-05 | 2006-09-01 | Alexion Pharmaceuticals, Inc. | Anticuerpos diseñados racionalmente. |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1416962A4 (en) | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | METHOD FOR IMPROVING THE COGNITIVE FUNCTION |
| AU2002331601B2 (en) | 2001-08-17 | 2006-04-13 | Tanox, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| US20050221382A1 (en) | 2002-03-18 | 2005-10-06 | Rother Russell P | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| CN105884893A (zh) | 2002-07-18 | 2016-08-24 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
| WO2004019861A2 (en) | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| PT1558648E (pt) | 2002-10-17 | 2012-04-23 | Genmab As | Anticorpos monoclonais humanos contra cd20 |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| WO2004056104A1 (en) | 2002-12-16 | 2004-07-01 | Koninklijke Philips Electronics N.V. | Personal video recorder method and user interface |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| JP2006516636A (ja) | 2003-01-30 | 2006-07-06 | メディミューン，インコーポレーテッド | 抗インテグリンαｖβ３抗体製剤及びその用途 |
| EP1592440A4 (en) | 2003-02-10 | 2007-07-11 | Elan Pharm Inc | IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| CA2522779A1 (en) * | 2003-04-25 | 2004-11-11 | Immunex Corporation | Inducers of recombinant protein expression |
| WO2005007809A2 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| CN1822857A (zh) | 2003-06-02 | 2006-08-23 | 阿莱克申药物公司 | 去免疫原性抗cd3抗体 |
| US20050027166A1 (en) | 2003-06-17 | 2005-02-03 | Shinya Matsumoto | Endoscope system for fluorescent observation |
| AT412877B (de) | 2003-07-01 | 2005-08-25 | Miba Gleitlager Gmbh | Schichtwerkstoff |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| WO2005092073A2 (en) | 2004-03-24 | 2005-10-06 | Pdl Biopharma, Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| EP1755674B1 (en) | 2004-05-14 | 2014-11-19 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| CN101223448B (zh) | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
| WO2007002571A2 (en) | 2005-06-23 | 2007-01-04 | Alexion Pharmaceuticals, Inc. | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
| EP1899477A4 (en) | 2005-07-01 | 2010-01-20 | Medimmune Inc | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS |
| WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| EP2918269A1 (en) | 2006-03-02 | 2015-09-16 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2007106585A1 (en) | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| WO2007130031A1 (en) | 2006-05-01 | 2007-11-15 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| EP2061810B1 (en) | 2006-09-05 | 2014-11-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
-
2007
- 2007-03-15 WO PCT/US2007/006606 patent/WO2007106585A1/en not_active Ceased
- 2007-03-15 ES ES16195355T patent/ES2965283T3/es active Active
- 2007-03-15 PL PL11001632T patent/PL2359834T3/pl unknown
- 2007-03-15 KR KR1020087024657A patent/KR20080110800A/ko not_active Ceased
- 2007-03-15 CA CA3022097A patent/CA3022097C/en active Active
- 2007-03-15 EP EP23198329.7A patent/EP4316465A3/en active Pending
- 2007-03-15 BR BRPI0708909A patent/BRPI0708909B8/pt active IP Right Grant
- 2007-03-15 HU HUE16195355A patent/HUE066795T2/hu unknown
- 2007-03-15 JP JP2009500498A patent/JP2009530299A/ja not_active Withdrawn
- 2007-03-15 IL IL302157A patent/IL302157A/en unknown
- 2007-03-15 EP EP16195355.9A patent/EP3167888B1/en active Active
- 2007-03-15 DK DK11001632.6T patent/DK2359834T5/en active
- 2007-03-15 US US12/225,040 patent/US20090220508A1/en not_active Abandoned
- 2007-03-15 KR KR1020147008290A patent/KR20140057635A/ko not_active Ceased
- 2007-03-15 HU HUE11001632A patent/HUE030105T2/en unknown
- 2007-03-15 CA CA2645810A patent/CA2645810C/en active Active
- 2007-03-15 AU AU2007225044A patent/AU2007225044C1/en active Active
- 2007-03-15 PT PT110016326T patent/PT2359834T/pt unknown
- 2007-03-15 PL PL16195355.9T patent/PL3167888T3/pl unknown
- 2007-03-15 MX MX2008011735A patent/MX340784B/es active IP Right Grant
- 2007-03-15 SI SI200731886T patent/SI2359834T1/sl unknown
- 2007-03-15 EP EP07753249A patent/EP2001490A1/en not_active Ceased
- 2007-03-15 EP EP11001632.6A patent/EP2359834B1/en not_active Revoked
- 2007-03-15 EP EP16172335.8A patent/EP3124029A1/en not_active Ceased
- 2007-03-15 ES ES11001632.6T patent/ES2612118T3/es active Active
- 2007-03-15 BR BR122017024057A patent/BR122017024057B8/pt active IP Right Grant
-
2008
- 2008-09-11 IL IL194041A patent/IL194041A/en active IP Right Grant
- 2008-09-12 MX MX2022002589A patent/MX2022002589A/es unknown
-
2012
- 2012-03-22 US US13/426,973 patent/US20120237515A1/en not_active Abandoned
-
2013
- 2013-10-23 JP JP2013219882A patent/JP2014015484A/ja not_active Withdrawn
-
2015
- 2015-12-03 JP JP2015236260A patent/JP6224059B2/ja active Active
-
2016
- 2016-05-06 US US15/148,839 patent/US9718880B2/en active Active
- 2016-09-09 US US15/260,888 patent/US9725504B2/en active Active
- 2016-10-03 US US15/284,015 patent/US9732149B2/en active Active
-
2017
- 2017-02-20 JP JP2017028811A patent/JP2017082017A/ja not_active Withdrawn
- 2017-05-14 IL IL252260A patent/IL252260B/en active IP Right Grant
- 2017-07-05 US US15/642,096 patent/US10590189B2/en active Active
-
2018
- 2018-04-08 IL IL258548A patent/IL258548A/en unknown
- 2018-07-25 JP JP2018139327A patent/JP2018165277A/ja not_active Withdrawn
-
2019
- 2019-10-08 JP JP2019185225A patent/JP2020002176A/ja not_active Withdrawn
-
2020
- 2020-01-23 US US16/750,978 patent/US20200392216A1/en not_active Abandoned
- 2020-02-28 US US16/804,567 patent/US10703809B1/en active Active
-
2021
- 2021-02-17 JP JP2021023314A patent/JP2021073319A/ja not_active Withdrawn
-
2022
- 2022-12-28 JP JP2022211659A patent/JP2023026536A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025091052A patent/JP2025120217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034978A5 (enExample) | ||
| CY1124675T1 (el) | Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2012255026A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2016539157A5 (enExample) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| JP2017506624A5 (enExample) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| JP2016523260A5 (enExample) | ||
| JP2017537912A5 (enExample) | ||
| CR20160483A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| JP2015516419A5 (enExample) | ||
| WO2016074641A8 (zh) | Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 | |
| JP2014148552A5 (enExample) | ||
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| JP2015509917A5 (enExample) |